Sorafenib in advanced hepatocellular carcinoma: A nationwide retrospective study of efficacy and tolerability

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Køstner, Anne Helene ^a   Sorensen, Morten ^b   Olesen, René Krøjgaard ^a   Grønbæk, Henning ^a   Lassen, Ulrik ^b   Ladekarl, Morten ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; LIVER; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME;

AGED; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; HYPERTENSION; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874545768     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/931972     Document Type: Article

References (16)

1. Lau Y. K., Sorafenib: new reference standard for systemic treatment of advanced hepatocellular carcinoma. Community Oncology 2007 4 9 529 530 2-s2.0-35348976055
2. EMEA, Nexavar: summary of product characteristics. Report 2009
3. Cheng A. L., Kang Y. K., Chen Z., Tsao C. J., Qin S., Kim J. S., Luo R., Feng J., Ye S., Yang T. S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W. Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 2009 10 1 25 34 2-s2.0-57749189578 10.1016/S1470-2045(08)70285-7
4. Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., De Oliveira A. C., Santoro A., Raoul J. L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T. F., Galle P. R., Seitz J. F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 4 378 390 2-s2.0-47949116252 10.1056/NEJMoa0708857
5. Di Maio M. M., Daniele B., Perrone F., Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nature Reviews Clinical Oncology 2009 6 9 505 506 2-s2.0-70450187411 10.1038/nrclinonc.2009.114
6. Venook A., Lencioni R., Marrero M., Nakajima K., Ye S., First interim results of the global investigation of therapeutic decisions in hepatocellular carcinoma (HCC) and of its treatment with sorafenib (GIDEON) study: use of sorafenib (Sor) by oncologists and nononcologists in the management of HCC. Journal of Clinical Oncology 2011 29 4, abstract 157
7. Shao Y. Y., Lin Z. Z., Hsu C., Shen Y. C., Hsu C. H., Cheng A. L., Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010 116 19 4590 4596 2-s2.0-77957559384 10.1002/cncr.25257
8. Chan S. L., Mo F. K. F., Johnson P. J., Hui E. P., Ma B. B. Y., Ho W., Lam K. C., Chan A. T. C., Mok T. S. K., Yeo W., New utility of an old marker: serial α -fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. Journal of Clinical Oncology 2009 27 3 446 452 2-s2.0-58749090909 10.1200/JCO.2008.18.8151
9. Bruix J., Sherman M., Llovet J. M., Beaugrand M., Lencioni R., Burroughs A. K., Christensen E., Pagliaro L., Colombo M., Rodés J., Clinical management of hepatocellular carcinoma: conclusions of the barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology 2001 35 3 421 430 2-s2.0-0034856294 10.1016/S0168-8278(01)00130-1 (Pubitemid 32844200)
10. Colevas A. D., Setser A., The NCI common terminology criteria for adverse events (CTCAE) v 3. 0 is the new standard for oncology clinical trials. Journal of Clinical Oncology 2004 22, article 6098
11. Hall W. H., Ramachandran R., Narayan S., Jani A. B., Vijayakumar S., An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004 4, article 94 2-s2.0-13144300880 10.1186/1471-2407-4-94 (Pubitemid 40180260)
12. Wörns M. A., Weinmann A., Pfingst K., Schulte-Sasse C., Messow C. M., Schulze-Bergkamen H., Teufel A., Schuchmann M., Kanzler S., Düber C., Otto G., Galle P. R., Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Journal of Clinical Gastroenterology 2009 43 5 489 495 2-s2.0-67651095716 10.1097/MCG.0b013e31818ddfc6
13. Sacco R., Bargellini I., Gianluigi G., Bertini M., Bozzi E., Altomare E., Battaglia V., Romano A., Bertoni M., Capria A., Bresci G., Bartolozzi C., Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterology 2011 11, article 4 2-s2.0-78651395593 10.1186/1471-230X-11-4
14. So B. J., Bekaii-Saab T., Bloomston M. A., Patel T., Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. Journal of hematology & oncology 2008 1, article 18 2-s2.0-72449128320
15. Shim J. H., Park J. W., Choi J. I., Park B. J., Kim C. M., Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. Journal of Cancer Research and Clinical Oncology 2009 135 4 617 625 2-s2.0-61449163901 10.1007/s00432-008-0496-x
16. Balsom S. M., Li X., Trolli E., Rose J., Bloomston M., Patel T., Bekaii-Saab T. S., A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology 2010 78 3-4 210 212 2-s2.0-77951236058 10.1159/000313701